Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies

Novel therapies including kinase inhibitors (KI) have led to high and durable response in patients with chronic lymphocytic leukemia (CLL), however, some patients stop therapy. This study evaluates reasons for treatment changes among CLL patients who stopped KI in real-world practice. Sixty-nine US...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Biol Ther
Главные авторы: Mato, Anthony R., Samp, Jennifer C., Gauthier, Geneviève, Terasawa, Emi, Brander, Danielle M.
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2018
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989798/
https://ncbi.nlm.nih.gov/pubmed/29584544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1449616
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы